Modulation of the Immune Response Induced by Gene Electrotransfer of a Hepatitis C Virus DNA Vaccine in Nonhuman Primates
Overview
Authors
Affiliations
Induction of multispecific, functional CD4+ and CD8+ T cells is the immunological hallmark of acute self-limiting hepatitis C virus (HCV) infection in humans. In the present study, we showed that gene electrotransfer (GET) of a novel candidate DNA vaccine encoding an optimized version of the nonstructural region of HCV (from NS3 to NS5B) induced substantially more potent, broad, and long-lasting CD4+ and CD8+ cellular immunity than naked DNA injection in mice and in rhesus macaques as measured by a combination of assays, including IFN-gamma ELISPOT, intracellular cytokine staining, and cytotoxic T cell assays. A protocol based on three injections of DNA with GET induced a substantially higher CD4+ T cell response than an adenovirus 6-based viral vector encoding the same Ag. To better evaluate the immunological potency and probability of success of this vaccine, we have immunized two chimpanzees and have compared vaccine-induced cell-mediated immunity to that measured in acute self-limiting infection in humans. GET of the candidate HCV vaccine led to vigorous, multispecific IFN-gamma+CD8+ and CD4+ T lymphocyte responses in chimpanzees, which were comparable to those measured in five individuals that cleared spontaneously HCV infection. These data support the hypothesis that T cell responses elicited by the present strategy could be beneficial in prophylactic vaccine approaches against HCV.
Therapeutic strategies and promising vaccine for hepatitis C virus infection.
Adugna A Immun Inflamm Dis. 2023; 11(8):e977.
PMID: 37647422 PMC: 10461427. DOI: 10.1002/iid3.977.
[Development approaches for vaccines against hepatitis C virus infections].
Bankwitz D, Krey T, Pietschmann T Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2022; 65(2):183-191.
PMID: 35015104 PMC: 8749110. DOI: 10.1007/s00103-021-03477-9.
Hepatitis C virus DNA vaccines: a systematic review.
Shayeghpour A, Kianfar R, Hosseini P, Ajorloo M, Aghajanian S, Yaghoobi M Virol J. 2021; 18(1):248.
PMID: 34903252 PMC: 8667529. DOI: 10.1186/s12985-021-01716-8.
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?.
Echeverria N, Comas V, Aldunate F, Perbolianachis P, Moreno P, Cristina J World J Hepatol. 2021; 13(10):1234-1268.
PMID: 34786164 PMC: 8568586. DOI: 10.4254/wjh.v13.i10.1234.
Hepatitis C Virus Vaccine: Challenges and Prospects.
Duncan J, Urbanowicz R, Tarr A, Ball J Vaccines (Basel). 2020; 8(1).
PMID: 32079254 PMC: 7157504. DOI: 10.3390/vaccines8010090.